GlassScriptPhysician profile
Marlyn Lorenzo
NPI 1639107097
$41,552.89
in general payments reported to CMS, 2019-2025
53 companies · $4,036 in 2025
The $4,036 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,651 · 2021: $4,357 · 2022: $3,345 · 2023: $4,420 · 2024: $4,035 · 2025: $4,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,386.21 |
| Education | $104.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,476.84 | 2019-2025 | |
| Amgen INC. | $5,385.61 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $2,398.69 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $2,318.86 | 2019-2025 | |
| Ucb, INC. | $1,857.96 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,751.51 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $888.00 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $810.35 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $733.93 | 2019-2024 | Taltz |
| Glaxosmithkline, LLC. | $693.22 | 2019-2025 | Benlysta |
| Radius Health, INC. | $649.36 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $616.47 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $554.97 | 2022-2025 | Lupkynis |
| Horizon Therapeutics Plc | $526.22 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $395.04 | 2019-2025 | Actemra, Rituxan |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $248.93 | 2021-2025 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $244.57 | 2023-2025 | Idacio |
| Genzyme Corporation | $244.42 | 2019-2025 | |
| Octapharma USA, INC. | $241.93 | 2022-2025 | Octagam Immune Globulin (Human) |
| Mallinckrodt Enterprises LLC | $236.91 | 2019 | |
| Alexion Pharmaceuticals, INC. | $209.87 | 2020-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.00 | 2019-2024 | Cyltezo |
| Depuy Synthes Sales INC. | $181.40 | 2019-2025 | Monovisc, Orthovisc |
| Celgene Corporation | $176.95 | 2019 | |
| Sandoz INC. | $118.50 | 2023-2025 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $106.19 | 2019 | |
| Sobi, INC | $105.70 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $86.90 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Daiichi Sankyo INC. | $83.92 | 2020-2022 | |
| Bioventus LLC | $81.57 | 2025 | Durolane |
| Fidia Pharma USA INC. | $76.74 | 2019-2024 | Hym/Hyn, Hymovis |
| Kiniksa Pharmaceuticals International, Plc | $64.29 | 2024 | Arcalyst |
| Biocon Biologics INC | $63.77 | 2023-2024 | Hulio |
| Hikma Pharmaceuticals USA | $63.05 | 2019-2020 | |
| Pharming Healthcare, INC. | $62.87 | 2023-2024 | Ruconest |
| Mylan Institutional INC. | $52.34 | 2023 | Hulio |
| Tersera Therapeutics LLC | $49.81 | 2022-2024 | Quzyttir |
| Cumberland Pharmaceuticals, INC. | $48.67 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $44.51 | 2019-2023 | Uptravi, Opsumit |
| Pacira Therapeutics, INC. | $42.91 | 2019 | |
| Alvogen INC | $41.80 | 2024-2025 | Teriparatide |
| Scilex Pharmaceuticals INC. | $40.56 | 2024 | |
| Kyowa Kirin, INC. | $35.92 | 2023-2025 | Crysvita |
| Janssen Pharmaceuticals, INC | $34.33 | 2025 | Tremfya |
| Tonix Medicines, INC. | $31.72 | 2025 | Tonmya |
| Merck Sharp & Dohme LLC | $30.10 | 2019 | |
| Janssen Scientific Affairs, LLC | $29.48 | 2019 | |
| Invivyd INC | $28.95 | 2024 | Pemgarda |
| Antares Pharma, INC. | $28.89 | 2020-2021 | |
| Oxford Immunotec USA INC | $23.61 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $23.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlyn Lorenzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.